By Karen Roman Abacus Global Management, Inc. (Nasdaq: ABL) said second quarter total sales increased 93% to $56.2 million ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...